Ailux Appoints Maria G. Belvisi CSO
Analysis based on 7 articles · First reported Apr 10, 2026 · Last updated Apr 10, 2026
The appointment of Maria G. Belvisi as Chief Scientific Officer of Ailux is expected to accelerate Ailux's drug development, potentially increasing its market value and competitive position in the biotechnology sector. This move signals a strategic expansion for Ailux, which could attract further investment and partnerships, positively impacting its parent company XtalPi.
Ailux, an AI-native biotech company and wholly-owned subsidiary of XtalPi, announced the appointment of Maria G. Belvisi, Ph.D. as its Chief Scientific Officer on April 9, 2026. Maria G. Belvisi, who previously served as Senior Vice President at AstraZeneca, brings over three decades of experience in drug research and development. Her appointment is set to accelerate Ailux's transition from AI-native biologics discovery to a fully integrated drug development organization, with a target for first clinical entry by 2027. Maria G. Belvisi will lead Ailux's scientific strategy, new program development, and establish a new UK research site to complement existing Shanghai capabilities. This strategic hire is seen as crucial for Ailux's goal of delivering transformative therapies to patients, leveraging its proprietary AI biologics platforms and global team.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard